Metabolic Alterations driven by PFKFB3 upregulation confer Resistance to Trastuzumab in HER2-Positive Breast Cancer.
Roos Vincken, Samuel Tanner Pasco, Veronica Steri, Laura Bozal‐Basterra, Wilfred F. J. van IJcken, Arkaitz Carracedo, Danny Huylebroeck, Mark M. Moasser, Ana Ruiz-Sáenz
This study identifies PFKFB3 upregulation as a driver of trastuzumab resistance in HER2+ breast cancer through metabolic rewiring and reduced ADCC, with clinical correlations to poor survival.
Biomedicine & Pharmacotherapy · Jan 1, 2026Peer-reviewedCancer Biology